Altimmune's Pemvidutide Shows Significant Fibrosis Regression in MASH Phase 2b Data at EASL 2026
ALT sits 16% above its 52-week low of $2.56.
Summary
Altimmune announced strong new Phase 2b IMPACT trial data for pemvidutide in MASH at EASL 2026. The data showed concurrent improvements across multiple non-invasive markers and significant qFibrosis-measured fibrosis regression at 24 weeks. Specifically, 68.6% of patients on the 1.2 mg dose and 54.5% on the 1.8 mg dose achieved at least one stage of qFibrosis regression, compared to 29.6% on placebo. This positive clinical update follows recent significant capital raises, including a $225 million public offering in April, which substantially bolstered the company's cash position. Strong Phase 2b data, particularly demonstrating fibrosis regression, is a major de-risking event for pemvidutide, Altimmune's lead drug candidate for MASH, significantly strengthening its commercial potential. The company plans to begin patient enrollment in its PERFORMA Phase 3 trial for pemvidutide in MASH in the second half of this year.
At the time of this announcement, ALT was trading at $2.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $569.8M. The 52-week trading range was $2.56 to $7.73. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.